A Multicenter, Retrospective, Medical Record Review Of The Effectiveness Of Lanreotide Following Treatment With Octreotide In Patients With Neuroendocrine Tumors
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Lanreotide (Primary) ; Octreotide
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Sponsors Ipsen
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 26 Jan 2018 Status changed from recruiting to completed.
- 28 Aug 2017 Planned End Date changed from 14 Jul 2017 to 14 Dec 2017.